[^1]
| Property | Value | [^2]
|---------|-------| [^3]
| **Gene Symbol** | CDK5R2 |
| **Full Name** | Cyclin-Dependent Kinase 5 Regulatory Subunit 2 |
| **Chromosomal Location** | 2q35 |
| **NCBI Gene ID** | [8941](https://www.ncbi.nlm.nih.gov/gene/8941) |
| **Ensembl ID** | ENSG00000100157 |
| **UniProt ID** | [Q16569](https://www.uniprot.org/uniprot/Q16569) |
| **Protein Name** | Cyclin-dependent kinase 5 activator 2 (p39) |
| **Expression** | Neuron-specific |
CDK5R2 (also known as p39) is a neuron-specific gene that encodes a regulatory subunit of CDK5, a proline-directed serine/threonine kinase critical for neuronal function. Unlike its ubiquitously expressed paralog CDK5R1 (p35), p39 is enriched in the brain and plays distinct roles in neuronal development, synaptic plasticity, and myelination. Variants in CDK5R2 have been associated with Alzheimer's Disease and other neurodegenerative conditions through dysregulation of tau phosphorylation and synaptic homeostasis.
CDK5R2 encodes p39, which forms an active complex with CDK5:
- Neuron-specific activation: p39 expression is largely restricted to neurons, making CDK5 activity in the brain uniquely regulated by this activator
- Alternative splicing: The CDK5R2 gene produces multiple isoforms with different tissue distributions and regulatory properties
- Calcium-dependent activation: p39 cleavage by calpain produces p25, a hyperactive fragment similar to p35 cleavage in disease states
p39/CDK5 signaling regulates multiple neuronal processes:
| Process |
Function |
Key Targets |
| Neuronal Development |
Axon guidance, dendrite formation |
CRMPs, MAPs |
| Synaptic Plasticity |
Long-term potentiation, memory formation |
Synaptic receptors, PSD proteins |
| Myelination |
Oligodendrocyte differentiation |
MBP, PLP |
| Cell Cycle Control |
Neuronal cell cycle exit |
Rb, E2F proteins |
CDK5R2 and CDK5R1 have overlapping but distinct functions:
- p35 (CDK5R1) is expressed earlier in development
- p39 (CDK5R2) becomes dominant in mature neurons
- Both activators can compensate for each other's loss
- p39 knockout mice show more severe neurological phenotypes than p35 knockouts
The p39 protein contains:
- N-terminal region: Regulatory domain responsible for CDK5 binding and activation
- Central region: Contains cleavage sites for calpain-mediated conversion to p25
- C-terminal domain: Required for proper subcellular localization
CDK5R2 dysregulation contributes to AD pathogenesis through multiple mechanisms:
- Tau Hyperphosphorylation: Enhanced CDK5/p39 activity leads to excessive tau phosphorylation at AD-relevant epitopes (Ser202, Thr231, Ser396)
- Synaptic Dysfunction: Alters synaptic protein phosphorylation, impairing neurotransmission
- Amyloid-β Interaction: Aβ can activate calpain, leading to p39 cleavage and CDK5 hyperactivation
- Neuroinflammation: CDK5/p39 signaling modulates microglial activation and inflammatory responses
- Parkinson's Disease: Altered expression in dopaminergic neurons
- Amyotrophic Lateral Sclerosis (ALS): Dysregulated in motor neurons
- Huntington's Disease: Implicated in mutant huntingtin toxicity
Genome-wide association studies (GWAS) have linked CDK5R2 variants to:
- Alzheimer's disease risk
- Cognitive decline in aging
- Schizophrenia susceptibility
p39 is expressed throughout the brain with highest levels in:
- Cerebral cortex: Especially layer V pyramidal neurons
- Hippocampus: CA1-CA3 regions, dentate gyrus
- Cerebellum: Purkinje cells
- Basal ganglia: Striatal medium spiny neurons
- Cytosolic: Majority of p39 is cytosolic
- Membrane-associated: Subset localizes to synapses
- Neuronal processes: Present in axons and dendrites
- Tsai et al., 2001 - Original characterization of p39 function in neurons
- Liu et al., 2007 - Comprehensive review of p39 in neuronal function
- Czonka et al., 2021 - CDK5R2 role in neurodegeneration mechanisms
- Shah et al., 2009 - CDK5R2 in brain development
CDK5/p39 activity represents a potential therapeutic target:
- Inhibitor development: Small molecules targeting the CDK5/p39 complex
- Calpain inhibition: Preventing p25 generation from p39
- Gene therapy: Modulating CDK5R2 expression levels
CDK5R2/p39 interacts with:
- CDK5 - Primary binding partner
- Tau - Phosphorylation substrate
- DARPP-32 - Modulator of CDK5 activity
- p35 - Can form heterodimers
- Synaptic proteins (PSD95, Synapsin)
== References ==